{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:59:48Z","timestamp":1790215188045,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011045","name":"Minist\u00e8re de l'Enseignement sup\u00e9rieur de la Recherche et de l'Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-22-CE18-0038"],"award-info":[{"award-number":["ANR-22-CE18-0038"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-22-PEBI-0007"],"award-info":[{"award-number":["ANR-22-PEBI-0007"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-21-ICRD-0009"],"award-info":[{"award-number":["ANR-21-ICRD-0009"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jconrel.2026.115271","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:59:38Z","timestamp":1787065178000},"page":"115271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Versatile lipoparticles for the co-delivery of TLR3 and TLR7\/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations"],"prefix":"10.1016","volume":"398","author":[{"given":"Valentine","family":"Ginet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Garapon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Ayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Djebali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Sohier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Olivier","family":"Vidalain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Verrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jconrel.2026.115271_bb0005","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/toxins15090563","article-title":"Recent developments in vaccine design: from live vaccines to recombinant toxin vaccines","volume":"15","author":"Gupta","year":"2023","journal-title":"Toxins"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115271_bb0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.biotechadv.2017.03.005","article-title":"Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines","volume":"35","author":"Moyle","year":"2017","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2026.115271_bb0015","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"17","key":"10.1016\/j.jconrel.2026.115271_bb0020","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1039\/D3TB02861E","article-title":"Vaccine adjuvants: current status, research and development, licensing, and future opportunities","volume":"12","author":"Cui","year":"2024","journal-title":"J. Mater. Chem. B"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115271_bb0025","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2517137","article-title":"Advances in vaccine adjuvant development and future perspectives","volume":"32","author":"Sinani","year":"2025","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115271_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126180","article-title":"Recent advances in vaccine adjuvants: from lab to clinic","volume":"684","author":"Vardikar","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115271_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10663","article-title":"Vaccine adjuvants for infectious disease in the clinic","volume":"9","author":"Goetz","year":"2024","journal-title":"Bioeng. Transl. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115271_bb0040","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2217\/imt.09.70","article-title":"Toll-like receptor agonists in cancer therapy","volume":"1","author":"Adams","year":"2009","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115271_bb0045","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2217\/imt.13.24","article-title":"Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies","volume":"5","author":"Baxevanis","year":"2013","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115271_bb0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/pharmaceutics14020423","article-title":"Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115271_bb0055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","article-title":"Decoding Toll-like receptors: recent insights and perspectives in innate immunity","volume":"57","author":"Kawai","year":"2024","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115271_bb0060","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115271_bb0065","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.106443","article-title":"Toll-like receptors (TLRs) in the trained immunity era","volume":"14","author":"Alexopoulou","year":"2025","journal-title":"eLife"},{"issue":"33","key":"10.1016\/j.jconrel.2026.115271_bb0070","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","article-title":"Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction","volume":"29","author":"Smirnov","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2026.115271_bb0075","doi-asserted-by":"crossref","first-page":"113803","DOI":"10.1016\/j.addr.2021.05.013","article-title":"Evolution of Toll-like receptor 7\/8 agonist therapeutics and their delivery approaches: from antiviral formulations to vaccine adjuvants","volume":"175","author":"Bhagchandani","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115271_bb0080","doi-asserted-by":"crossref","first-page":"622614","DOI":"10.3389\/fimmu.2020.622614","article-title":"TLR agonists as mediators of trained immunity: mechanistic insight and immunotherapeutic potential to combat infection","volume":"11","author":"Owen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115271_bb0085","doi-asserted-by":"crossref","first-page":"102172","DOI":"10.1016\/j.cbpa.2022.102172","article-title":"Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics","volume":"70","author":"Kaur","year":"2022","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115271_bb0090","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.autrev.2015.05.014","article-title":"On vaccine\u2019s adjuvants and autoimmunity: current evidence and future perspectives","volume":"14","author":"Pellegrino","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"Pt 1","key":"10.1016\/j.jconrel.2026.115271_bb0095","doi-asserted-by":"crossref","first-page":"134620","DOI":"10.1016\/j.ijbiomac.2024.134620","article-title":"Conjugation of TLR7 and TLR7\/8 agonists onto weak protein antigen via versatile oxime ligation for enhanced vaccine efficacy","volume":"278","author":"Zhang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2026.115271_bb0100","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2023.01.062","article-title":"Novel sialoglycan linkage for constructing adjuvant-protein conjugate as potent vaccine for COVID-19","volume":"355","author":"Wen","year":"2023","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.jconrel.2026.115271_bb0105","doi-asserted-by":"crossref","first-page":"113940","DOI":"10.1016\/j.jconrel.2025.113940","article-title":"Advanced rational design of polymeric nanoparticles for the controlled delivery of biologics","volume":"384","author":"Rodriguez-Cruz","year":"2025","journal-title":"J. Control. Release"},{"issue":"21","key":"10.1016\/j.jconrel.2026.115271_bb0110","doi-asserted-by":"crossref","first-page":"13440","DOI":"10.3390\/ijms232113440","article-title":"Mucosal adjuvants delivered by a mucoadhesive patch for sublingual administration of subunit vaccines","volume":"23","author":"Monge","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115271_bb0115","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/ni1223","article-title":"Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1\u2013polarizing program in dendritic cells","volume":"6","author":"Napolitani","year":"2005","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115271_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155650","article-title":"Powerful complex immunoadjuvant based on synergistic effect of combined TLR4 and NOD2 activation significantly enhances magnitude of humoral and cellular adaptive immune responses","volume":"11","author":"Tukhvatulin","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115271_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201253","article-title":"Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves","volume":"13","author":"Thakur","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.115271_bb0130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2018.04.041","article-title":"Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy","volume":"282","author":"Kuai","year":"2018","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115271_bb0135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.tibtech.2018.10.004","article-title":"Applications of immunomodulatory immune synergies to adjuvant discovery and vaccine development","volume":"37","author":"Tom","year":"2019","journal-title":"Trends Biotechnol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115271_bb0140","doi-asserted-by":"crossref","first-page":"13329","DOI":"10.1021\/acsnano.1c03093","article-title":"Synergistic immunostimulation through the dual activation of toll-like receptor 3\/9 with spherical nucleic acids","volume":"15","author":"Huang","year":"2021","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115271_bb0145","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41565-022-01296-w","article-title":"A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion","volume":"18","author":"Jin","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115271_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202404335","article-title":"Co-delivery of multiple toll-like receptor agonists and avian influenza hemagglutinin on protein nanoparticles enhances vaccine immunogenicity and efficacy","volume":"14","author":"Ramirez","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.115271_bb0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejpb.2021.02.010","article-title":"Recent update of toxicity aspects of nanoparticulate systems for drug delivery","volume":"161","author":"Patnaik","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115271_bb0160","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/bs.pmbts.2024.01.001","article-title":"Advances in the polymeric nanoparticulate delivery systems for RNA therapeutics","volume":"204","author":"Sristi","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2026.115271_bb0165","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/IJN.S198353","article-title":"Lipid\u2013polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives","volume":"14","author":"Mukherjee","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.115271_bb0170","doi-asserted-by":"crossref","first-page":"100570","DOI":"10.1016\/j.colcom.2021.100570","article-title":"Lipid polymer hybrid nanocarriers: insights into synthesis aspects, characterization, release mechanisms, surface functionalization and potential implications","volume":"46","author":"Shah","year":"2022","journal-title":"Colloid Interface Sci. Commun."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115271_bb0175","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.nano.2012.11.010","article-title":"Core\u2013shell-type lipid\u2013polymer hybrid nanoparticles as a drug delivery platform","volume":"9","author":"Mandal","year":"2013","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115271_bb0180","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/pharmaceutics13030377","article-title":"LipoParticles: lipid-coated PLA nanoparticles enhanced in vitro mRNA transfection compared to liposomes","volume":"13","author":"Ayad","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115271_bb0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/1061186X.2017.1367006","article-title":"General overview of lipid\u2013polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes","volume":"26","author":"Wakaskar","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2026.115271_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2017.07.001","article-title":"Beyond liposomes: recent advances on lipid based nanostructures for poorly soluble\/poorly permeable drug delivery","volume":"68","author":"Teixeira","year":"2017","journal-title":"Prog. Lipid Res."},{"issue":"758","key":"10.1016\/j.jconrel.2026.115271_bb0195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn6605","article-title":"A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates","volume":"16","author":"Arunachalam","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"48","key":"10.1016\/j.jconrel.2026.115271_bb0200","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb1025","article-title":"3M-052, a synthetic TLR-7\/8 agonist induces durable HIV-1 envelope specific plasma cells and humoral immunity in non-human primates","volume":"5","author":"Kasturi","year":"2020","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115271_bb0205","doi-asserted-by":"crossref","first-page":"46426","DOI":"10.1038\/srep46426","article-title":"A formulated TLR7\/8 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines","volume":"7","author":"Van Hoeven","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115271_bb0210","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91020","article-title":"TLR7\/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth","volume":"2","author":"Dowling","year":"2017","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.jconrel.2026.115271_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr2631","article-title":"Generation of an inflammatory niche in a hydrogel depot through recruitment of key immune cells improves efficacy of mRNA vaccines","volume":"11","author":"Meany","year":"2025","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115271_bb0220","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.vaccine.2008.10.024","article-title":"A clinical grade poly I:C-analogue (Ampligen\u00ae) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro","volume":"27","author":"Navabi","year":"2009","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115271_bb0225","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.4049\/jimmunol.181.11.7670","article-title":"Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha\/beta","volume":"181","author":"Ngoi","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115271_bb0230","doi-asserted-by":"crossref","first-page":"1334800","DOI":"10.3389\/fimmu.2023.1334800","article-title":"Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors","volume":"14","author":"Anfray","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115271_bb0235","doi-asserted-by":"crossref","first-page":"101564","DOI":"10.1016\/j.omtm.2025.101564","article-title":"Nanoparticle delivery of AMPK activator 991 prevents its toxicity and improves muscle homeostasis in Duchenne muscular dystrophy","volume":"33","author":"Andreana","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2026.115271_bb0240","doi-asserted-by":"crossref","first-page":"115104","DOI":"10.1016\/j.ejmech.2023.115104","article-title":"Ras superfamily GTPase activating proteins in cancer: potential therapeutic targets?","volume":"248","author":"Xiao","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115271_bb0245","doi-asserted-by":"crossref","first-page":"19570","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115271_bb0250","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fimmu.2019.01234","article-title":"On analyzing how the Th1\/Th2 phenotype of an immune response is determined: classical observations must not be ignored","volume":"10","author":"Bretscher","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115271_bb0255","doi-asserted-by":"crossref","first-page":"105483","DOI":"10.1016\/j.antiviral.2022.105483","article-title":"Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus","volume":"209","author":"Lamrayah","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2026.115271_bb0260","doi-asserted-by":"crossref","first-page":"812774","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115271_bb0265","article-title":"TLR agonists as adjuvants for viral vaccines: mechanisms, applications, and future directions","volume":"16","author":"Shao","year":"2025","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115271_bb0270","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1128\/CVI.00703-12","article-title":"Blueprints of signaling interactions between pattern recognition receptors: implications for the design of vaccine adjuvants","volume":"20","author":"Timmermans","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115271_bb0275","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acscentsci.8b00823","article-title":"Linked toll-like receptor triagonists stimulate distinct, combination-dependent innate immune responses","volume":"5","author":"Albin","year":"2019","journal-title":"ACS Cent. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115271_bb0280","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1016\/j.apsb.2022.05.032","article-title":"Spatio-temporal delivery of both intra- and extracellular toll-like receptor agonists for enhancing antigen-specific immune responses","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115271_bb0285","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1021\/acs.nanolett.9b00030","article-title":"Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy","volume":"19","author":"Zhang","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2026.115271_bb0290","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fbioe.2019.00259","article-title":"A perspective on polylactic acid-based polymers use for nanoparticles synthesis and applications","volume":"7","author":"Casalini","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115271_bb0295","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1124\/pr.115.012070","article-title":"Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come","volume":"68","author":"Yingchoncharoen","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115271_bb0300","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1039\/b804933e","article-title":"Polymer-supported lipid shells, onions, and flowers","volume":"4","author":"Bershteyn","year":"2008","journal-title":"Soft Matter"},{"key":"10.1016\/j.jconrel.2026.115271_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2024.1456939","article-title":"Recent advances in surface decoration of nanoparticles in drug delivery","volume":"6","author":"Ly","year":"2024","journal-title":"Front. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115271_bb0310","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.biomaterials.2018.12.019","article-title":"Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation","volume":"195","author":"Coolen","year":"2019","journal-title":"Biomaterials"},{"issue":"31","key":"10.1016\/j.jconrel.2026.115271_bb0315","doi-asserted-by":"crossref","first-page":"21365","DOI":"10.1039\/D3RA02969G","article-title":"Nanoparticle-based drug delivery systems targeting cancer cell surfaces","volume":"13","author":"Hong","year":"2023","journal-title":"RSC Adv."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115271_bb0320","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.3390\/v14112445","article-title":"CXCL10 chemokine: a critical player in RNA and DNA viral infections","volume":"14","author":"Elemam","year":"2022","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115271_bb0325","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2008-03-146720","article-title":"Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages","volume":"113","author":"Netea","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115271_bb0330","doi-asserted-by":"crossref","first-page":"109728","DOI":"10.1016\/j.celrep.2021.109728","article-title":"Single-cell secretion analysis reveals a dual role for IL-10 in restraining and resolving the TLR4-induced inflammatory response","volume":"36","author":"Alexander","year":"2021","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115271_bb0335","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd4235","article-title":"TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation","volume":"7","author":"Pradhan","year":"2021","journal-title":"Sci. Adv."},{"issue":"13","key":"10.1016\/j.jconrel.2026.115271_bb0340","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1128\/JVI.00262-16","article-title":"HIV-1 tat protein activates both the MyD88 and TRIF pathways to induce tumor necrosis factor alpha and interleukin-10 in human monocytes","volume":"90","author":"Plan\u00e8s","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2026.115271_bb0345","article-title":"Interferon-\u03b2 paracrine signaling mediates synergy between TLR3 and TRIF-independent TLR pathways","author":"Rocha","year":"2025","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115271_bb0350","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nri.2015.8","article-title":"Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease","volume":"16","author":"Cao","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115271_bb0355","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115271_bb0360","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41423-025-01358-8","article-title":"IL-1 family cytokines in inflammation and immunity","volume":"22","author":"Garlanda","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115271_bb0365","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1038\/s41598-019-39048-x","article-title":"The diagnostic accuracy of Th1 (IFN-\u03b3, TNF-\u03b1, and IL-2) and Th2 (IL-4, IL-6 and IL-10) cytokines response in AFB microscopy smear negative PTB- HIV co-infected patients","volume":"9","author":"Kisuya","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115271_bb0370","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.fsi.2021.07.022","article-title":"Characterisation and analysis of IFN-gamma producing cells in rainbow trout Oncorhynchus mykiss","volume":"117","author":"Hu","year":"2021","journal-title":"Fish Shellfish Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115271_bb0375","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jconrel.2013.01.015","article-title":"Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties","volume":"167","author":"Pavot","year":"2013","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115271_bb0380","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/pharmaceutics14010107","article-title":"A polylactide-based micellar adjuvant improves the intensity and quality of immune response","volume":"14","author":"Lamrayah","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115271_bb0385","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2006.02.006","article-title":"Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models","volume":"112","author":"Ataman-Onal","year":"2006","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115271_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115271_bb0395","doi-asserted-by":"crossref","first-page":"e26887","DOI":"10.1016\/j.heliyon.2024.e26887","article-title":"Poly(I:C) and R848 ligands show better adjuvanticity to induce B and T cell responses against the antigen(s)","volume":"10","author":"Tandel","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2026.115271_bb0400","doi-asserted-by":"crossref","first-page":"1705839","DOI":"10.3389\/fimmu.2026.1705839","article-title":"Poly(I:C) and R848 adjuvants elicit sizeable humoral immunity to liver stage malaria antigens","volume":"17","author":"Tandel","year":"2026","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115271_bb0405","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7774\/cevr.2024.13.1.10","article-title":"Humanized mouse model for vaccine evaluation: an overview","volume":"13","author":"Kaushik","year":"2024","journal-title":"Clin. Exp. Vaccine Res."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115271_bb0410","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1232219","article-title":"Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses","volume":"5","author":"Hotz","year":"2016","journal-title":"Oncoimmunology"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:59:23Z","timestamp":1790211563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926006759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":82,"alternative-id":["S0168365926006759"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115271","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Versatile lipoparticles for the co-delivery of TLR3 and TLR7\/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115271"}}